# Athenex Inc. (ATNX)

Source: https://www.quantisnow.com/company/ATNX
Generated: 2026-11-17T04:46:50.515Z

- Ticker: ATNX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2017
- Website: athenex.com

## About

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

## Latest ATNX news and filings

- 2023-10-02 11:42 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Leadership Update](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-completion-of-acquisition-or-4996199)
- 2023-08-17 20:06 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-leadership-update-4912638)
- 2023-07-18 13:03 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Leadership Update](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-entry-into-a-material-4764598)
- 2023-05-24 16:49 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Wednesday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-wednesday-4552429)
- 2023-05-23 12:03 UTC [SEC Form NT 10-Q filed by Athenex Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-athenex-inc-4543336)
- 2023-05-22 20:15 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-bankruptcy-or-receivership-events-4540324)
- 2023-05-22 16:08 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Monday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-monday-4538649)
- 2023-05-15 18:47 UTC [Market Insight] [Nasdaq Rises 75 Points; Tower Semiconductor Posts Upbeat Q1 Results](https://www.quantisnow.com/insight/nasdaq-rises-75-points-tower-semiconductor-posts-upbeat-q1-results-4504809)
- 2023-05-15 17:45 UTC [Market Insight] [Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.quantisnow.com/insight/why-venus-concept-shares-are-trading-lower-by-over-15-4504262)
- 2023-05-15 17:31 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-intraday-session-4504163)
- 2023-05-15 16:00 UTC [Market Insight] [Crude Oil Rises 1.5%; Athenex Shares Plummet](https://www.quantisnow.com/insight/crude-oil-rises-15-athenex-shares-plummet-4503325)
- 2023-05-15 15:11 UTC [Market Insight] [Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge](https://www.quantisnow.com/insight/athenex-voluntarily-filed-for-chapter-11-proceedings-shares-plunge-4502880)
- 2023-05-15 13:55 UTC [Market Insight] [Why Athenex (ATNX) Stock Is Getting Obliterated Monday](https://www.quantisnow.com/insight/why-athenex-atnx-stock-is-getting-obliterated-monday-4502035)
- 2023-05-15 13:06 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-pre-market-session-4501474)
- 2023-05-15 12:43 UTC [Market Chatter] [Athenex shares are trading lower after the company announced it voluntarily filed Chapter 11 proceedings.](https://www.quantisnow.com/insight/athenex-shares-are-trading-lower-after-the-company-announced-it-4501017)
- 2023-05-15 12:03 UTC [Market Insight] [Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-neogames-shares-are-trading-higher-by-121-here-are-4500585)
- 2023-05-15 08:17 UTC [Market Chatter] [Athenex Announced That, Following An Ongoing Strategic Review, It Has Agreed With Its Lenders To Move Forward With A Sales Process Of Its Assets Across Its Primary Businesses; To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings](https://www.quantisnow.com/insight/athenex-announced-that-following-an-ongoing-strategic-review-it-has-4499140)
- 2023-05-14 15:15 UTC [Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process](https://www.quantisnow.com/insight/athenex-inc-reaches-agreement-with-lenders-to-pursue-expedited-sales-4498896)
- 2023-05-12 13:06 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-pre-market-session-4493572)
- 2023-05-08 20:36 UTC [SEC Form 4] [SEC Form 4 filed by Lau Johnson Yiu Nam](https://www.quantisnow.com/insight/sec-form-4-filed-by-lau-johnson-yiu-nam-4463642)
- 2023-05-08 20:33 UTC [SEC Form 4] [SEC Form 4 filed by Kwan Rudolf](https://www.quantisnow.com/insight/sec-form-4-filed-by-kwan-rudolf-4463586)
- 2023-05-08 20:29 UTC [SEC Form 4] [SEC Form 4 filed by Cook Timothy Devere](https://www.quantisnow.com/insight/sec-form-4-filed-by-cook-timothy-devere-4463495)
- 2023-05-03 20:17 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-notice-of-delisting-or-4438592)
- 2023-05-01 17:01 UTC [Market Chatter] [Quantum Leap Healthcare Collaborative Announces Result Of Oral Paclitaxel In Combination With A PD-1 And Carboplatin From I-SPY2 TRIAL At ASCO](https://www.quantisnow.com/insight/quantum-leap-healthcare-collaborative-announces-result-of-oral-paclitaxel-in-4418964)
- 2023-04-28 12:10 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by Athenex Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-athenex-inc-amendment-4404647)
- 2023-04-25 21:23 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-leadership-update-4383458)
- 2023-04-24 20:53 UTC [SEC Form 4] [SEC Form 4 filed by Wu Jinn](https://www.quantisnow.com/insight/sec-form-4-filed-by-wu-jinn-4375320)
- 2023-04-24 20:51 UTC [SEC Form 4] [SEC Form 4 filed by Vierling John](https://www.quantisnow.com/insight/sec-form-4-filed-by-vierling-john-4375308)
- 2023-04-24 20:48 UTC [SEC Form 4] [SEC Form 4 filed by Tsang Benson Kwan Hung](https://www.quantisnow.com/insight/sec-form-4-filed-by-tsang-benson-kwan-hung-4375282)
- 2023-04-24 20:45 UTC [SEC Form 4] [SEC Form 4 filed by Spiegel Robert J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-spiegel-robert-j-4375250)
- 2023-04-24 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Lau Johnson Yiu Nam](https://www.quantisnow.com/insight/sec-form-4-filed-by-lau-johnson-yiu-nam-4375201)
- 2023-04-24 20:38 UTC [SEC Form 4] [SEC Form 4 filed by Kwan Rudolf](https://www.quantisnow.com/insight/sec-form-4-filed-by-kwan-rudolf-4375177)
- 2023-04-24 20:36 UTC [SEC Form 4] [SEC Form 4 filed by Fok Manson](https://www.quantisnow.com/insight/sec-form-4-filed-by-fok-manson-4375142)
- 2023-04-24 20:33 UTC [SEC Form 4] [SEC Form 4 filed by Davis Stephanie A](https://www.quantisnow.com/insight/sec-form-4-filed-by-davis-stephanie-a-4375093)
- 2023-04-24 20:29 UTC [SEC Form 4] [SEC Form 4 filed by Cook Timothy Devere](https://www.quantisnow.com/insight/sec-form-4-filed-by-cook-timothy-devere-4374982)
- 2023-04-11 20:36 UTC [SEC Form 4] [SEC Form 4 filed by Cook Timothy Devere](https://www.quantisnow.com/insight/sec-form-4-filed-by-cook-timothy-devere-4323179)
- 2023-04-11 20:33 UTC [SEC Form 4] [SEC Form 4 filed by Kwan Rudolf](https://www.quantisnow.com/insight/sec-form-4-filed-by-kwan-rudolf-4323151)
- 2023-04-11 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Lau Johnson Yiu Nam](https://www.quantisnow.com/insight/sec-form-4-filed-by-lau-johnson-yiu-nam-4323112)
- 2023-03-31 20:15 UTC [SEC Form 8-K] [Athenex Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athenex-inc-filed-sec-form-8-k-amendments-to-articles-of-4281849)
- 2023-03-27 20:33 UTC [SEC Form 4] [SEC Form 4 filed by Cook Timothy Devere](https://www.quantisnow.com/insight/sec-form-4-filed-by-cook-timothy-devere-4253536)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ATNX
- Earnings history: https://www.quantisnow.com/earnings/ATNX
- Dividend history: https://www.quantisnow.com/dividends/ATNX
- Insider transactions: https://www.quantisnow.com/insiders/ATNX
- Options chain: https://www.quantisnow.com/options/ATNX
- SEC 8-K filings only: https://www.quantisnow.com/company/ATNX/8-k
- RSS and alerts for ATNX: https://www.quantisnow.com/docs/rss-feeds.md
